Merck & Co hopes for foothold in early TNBC after Keytruda t...

Merck & Co has unveiled data from its immunotherapy Keytruda that could allow it to gain a foothold in the tough-to-treat triple negative breast cancer (TNBC) indication, and potentiall

Tecentriq beats rivals to EU breast cancer market

Study resurrects Merck’s hopes for Keytruda in breast cancer

NICE changes its mind on Novartis’ Kisqali for breast cancer

Scotland backs Pfizer’s Ibrance for breast cancer

Roche closes on EU approval for Tecentriq in breast cancer